ABC294640 | Sphingosine kinase 2 inhibitor

ABC294640 chemical structure

Available Options

Size:PriceQuantity 
5 mg$75.00
25 mg$240.00
Request Quote / Bulk / Custom Size
Product Inquiry

ABC294640 (915385-81-8) is a selective orally bioavailable inhibitor (IC50 = 60 µM) of sphingosine kinase 2 (SK2).1 Displayed efficacy alone or in combination with other chemotherapeutics in multiple cancer models.2 ABC204640 induced immunogenic cell death (ICD) by increasing the surface expression of the ICD marker calreticulin and synergized with anti-CTL4 therapy in several cancer models.3 It reduced the suppressive activity of monocytic myeloid-derived suppressor cells in the tumor microenvironment and promoted their differentiation into a mature immunogenic phenotype.4 Additionally, it enhanced anti-PD-1 therapy by the same mechanism.4

References/Citations:

  1. French et al. (2010) Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2; J. Pharmacol. Exp. Ther. 333 129
  2. Companioni et al. (2021) Targeting Sphingolipids for Cancer Therapy; Front. Oncol. 11 745092
  3. Maines et al. (2023) Opanganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy; Int. J. Mol. Sci. 24 16901
  4. Chakraborty et al. (2026) Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis; Nat. Commun. Epub ahead of print
915385-81-8, ABC294640 supplier, Opaganib supplier, SK2 inhibitor, Sphingosine kinase 2 inhibitor, Sphk2 inhibitor
Alternate Name:
Opaganib

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

ABC294640 (915385-81-8) is a selective orally bioavailable inhibitor (IC50 = 60 µM) of sphingosine kinase 2 (SK2).1 Displayed efficacy alone or in combination with other chemotherapeutics in multiple cancer models.2 ABC204640 induced immunogenic cell death (ICD) by increasing the surface expression of the ICD marker calreticulin and synergized with anti-CTL4 therapy in several cancer models.3 It reduced the suppressive activity of monocytic myeloid-derived suppressor cells in the tumor microenvironment and promoted their differentiation into a mature immunogenic phenotype.4 Additionally, it enhanced anti-PD-1 therapy by the same mechanism.4

References/Citations:

  1. French et al. (2010) Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2; J. Pharmacol. Exp. Ther. 333 129
  2. Companioni et al. (2021) Targeting Sphingolipids for Cancer Therapy; Front. Oncol. 11 745092
  3. Maines et al. (2023) Opanganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy; Int. J. Mol. Sci. 24 16901
  4. Chakraborty et al. (2026) Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis; Nat. Commun. Epub ahead of print